Lepu Jiantang Pharmaceutical

Lepu Jiantang Pharmaceutical is a biotechnology subsidiary of Lepu Medical, focused on the development of innovative oncology therapeutics, particularly in the field of immunotherapy. The company's pipeline features advanced biologics including monoclonal and bispecific antibodies targeting immune checkpoints such as PD-1 and CTLA-4. Its lead candidate, puciglituzumab (HX008), is a humanized anti-PD-1 monoclonal antibody that has undergone extensive clinical evaluation for various solid tumors. Lepu Jiantang leverages the manufacturing and commercial infrastructure of its parent company to advance its clinical programs toward commercialization in the Chinese market.